Why Alcohol Use Disorder Needs New Treatments#
Alcohol use disorder (AUD) affects millions of Americans as well as people around the world,,. Alcohol use, including AUD, is a major cause of disability and preventable illness and death worldwide. There are medications available, such as naltrexone and acamprosate, that can help people stay abstinent or cut down on heavy drinking, but the benefit is modest, naltrexone helps more with heavy drinking and acamprosate more with abstinence, and not everyone responds in the same way. Substance use disorders, including AUD, are in desperate need for additional therapeutic approaches.
What Is Pemvidutide?#
A medication being developed by Altimmune, called pemvidutide, activates GLP-1 receptors as well as glucagon receptors,. GLP-1, as discussed in previous articles, is a hormone involved in the regulation of metabolism. Glucagon is a hormone made in the pancreas that acts on the liver to help regulate blood sugar.
How Pemvidutide Could Address Alcohol-Related Metabolic Complications#
One of the most interesting aspects of pemvidutide is that, because it also activates the glucagon receptor, it may help with alcohol-related liver disease. This is being tested in the Phase 2 RESTORE trial, and it has not yet been shown,. Unlike semaglutide, which primarily targets GLP-1 receptors, or tirzepatide, which activates GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, pemvidutide combines GLP-1 and glucagon receptor activation,,.
What Did the Pemvidutide Clinical Trial Find?#
In November 2026, Altimmune presented results from the RECLAIM Phase 2 trial, which evaluated pemvidutide in adults with alcohol use disorder and a BMI above 25 kg/m², meaning they were overweight or obese. Approximately 100 participants enrolled, and they received either pemvidutide 2.4 mg or placebo once a week for 24 weeks,. Participants receiving pemvidutide had an average reduction of 4.20 heavy drinking days per week, compared with 2.75 days in the placebo group,. Even people in the placebo group had a reduction in heavy drinking days (about 2.75 fewer per week). This is common in alcohol trials and likely reflects placebo response, regular monitoring, trial participation and natural improvement. However, it remains promising that people who were treated with pemvidutide had a greater reduction compared to placebo.
This represented a treatment difference of 1.45 fewer heavy drinking days per week,,.
Additional findings were encouraging:
- 42.2% of pemvidutide-treated participants achieved zero heavy drinking days, compared with 17.4% receiving placebo,.
- 64.4% achieved at least a two-level reduction in World Health Organization drinking-risk categories, compared with 34.8% receiving placebo,.
- Alcohol abstinence days increased, with favorable differences compared with placebo,.
- Phosphatidylethanol (PEth), an objective biomarker of alcohol consumption, also declined significantly,,,,.
These findings are particularly notable because they demonstrate changes in both self-reported drinking behavior and an objective biological measure of alcohol exposure.
Nevertheless, these are Phase 2 results reported by the trial sponsor, and larger confirmatory studies are needed before pemvidutide can be considered an established addiction treatment.
Could Pemvidutide Also Protect the Liver?#
One of pemvidutide's potentially distinguishing features is its dual metabolic mechanism.
Chronic heavy alcohol consumption can lead to many problems with the liver, including fatty liver, or hepatic steatosis, inflammation, fibrosis (when the liver tissue begins to scar), and eventually cirrhosis, which is advanced, permanent scarring of the liver that can lead to liver failure,. The liver is an essential organ in our body, and without it, our body cannot function.
Glucagon receptor activation has metabolic effects involving helping the liver use energy efficiently, while GLP-1 receptor activation can contribute to improvements in weight and metabolic regulation,.
In the RECLAIM trial, pemvidutide-treated participants experienced approximately 8.7% mean weight loss over 24 weeks, compared with a slight weight increase in the placebo group.
In the RECLAIM trial, among participants with elevated baseline FIB-4, a noninvasive fibrosis risk score, about half of those on pemvidutide normalized it, compared with 17% on placebo, according to the company's early report.
However, improvements in metabolic liver disease cannot automatically be generalized to alcohol-associated liver disease.
A separate Phase 2 trial, RESTORE, is investigating pemvidutide specifically for alcohol-associated liver disease.
If future studies demonstrate meaningful benefits in both alcohol consumption and liver-related outcomes, pemvidutide could potentially address two interconnected aspects of alcohol use disorder.
Despite promising findings, pemvidutide remains investigational and is not FDA-approved for alcohol use disorder or any other indication.
The Medical Complications of Alcohol Use Disorder#
AUD is especially complicated because patients deal with not only compulsive alcohol drinking, but also with several life-threatening medical complications. For example, people can suffer from liver disease and ultimately liver failure, bleeding from veins in the esophagus, malnutrition, and Wernicke-Korsakoff syndrome, a brain disorder caused by thiamine deficiency that can leave lasting memory loss,. All of these complications can be fatal, which make it even more important for new and better treatments to be developed, especially ones that target the medical complications of AUD as well.
Why GLP-1 Medications Are Being Studied for Addiction#
As discussed in previous articles, GLP-1 is a hormone that not only plays a role in metabolism, but also affects the brain and how we process the rewarding aspects of food and other substances,. This is why these new medications have been investigated as potential treatments for addiction: addictive substances act on some of the same brain reward pathways that GLP-1 influences, although clinical evidence is still early,.
A New Approach to Psychiatric and Substance Use Disorders#
Treating psychiatric disorders and substance use disorders with a different mechanism, such as targeting GLP-1 receptors, represents an entirely new way of approaching these conditions.
Frequently Asked Questions#
What is pemvidutide?#
Pemvidutide is a medication being developed by Altimmune that activates GLP-1 receptors as well as glucagon receptors. It remains investigational and is not FDA-approved for alcohol use disorder or any other indication.
What did the RECLAIM trial find?#
In the RECLAIM Phase 2 trial, approximately 100 adults with moderate-to-severe AUD who were categorized as overweight or obese received pemvidutide 2.4 mg or placebo once a week for 24 weeks. Participants receiving pemvidutide had an average reduction of 4.20 heavy drinking days per week, compared with 2.75 days in the placebo group, a treatment difference of 1.45 fewer heavy drinking days per week. Other findings included more participants reaching zero heavy drinking days (42.2% versus 17.4%) and at least a two-level reduction in World Health Organization drinking-risk categories (64.4% versus 34.8%), more alcohol abstinence days, a significant decline in PEth, and about 8.7% mean weight loss over 24 weeks. These are Phase 2 results reported by the trial sponsor, and larger confirmatory studies are needed before pemvidutide can be considered an established addiction treatment.
Could pemvidutide also help the liver?#
Because pemvidutide also activates glucagon receptors, it has potential to treat alcohol-related metabolic complications. Some measures associated with liver health improved in RECLAIM, and pemvidutide has demonstrated improvements in steatohepatitis resolution in clinical trials involving MASH. Improvements in metabolic liver disease cannot automatically be generalized to alcohol-associated liver disease. A separate Phase 2 trial, RESTORE, is investigating pemvidutide specifically for alcohol-associated liver disease.
Is pemvidutide approved for alcohol use disorder?#
No. Despite promising findings, pemvidutide remains investigational and is not FDA-approved for alcohol use disorder or any other indication.




